<DOC>
	<DOCNO>NCT03093324</DOCNO>
	<brief_summary>This study assess gastrointestinal ( GI ) tolerability ALKS 8700 adult subject RRMS</brief_summary>
	<brief_title>A Tolerability Study ALKS 8700 Subjects With Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Capable understand comply protocol Has confirm diagnosis RRMS Neurologically stable evidence relapse within 30 day prior randomization Agrees use acceptable method contraception duration study 30 day study drug administration , surgically sterile postmenopausal Additional criterion may apply Have finding ( ) would compromise safety subject , affect subject 's ability adhere protocol visit schedule fulfill visit requirement , would make subject unsuitable participation study Diagnosis primary progressive , secondary progressive , progressive relapse MS History clinically significant cardiovascular , pulmonary , GI , dermatologic , psychiatric , neurologic ( MS ) , endocrine , renal , and/or major disease would preclude participation clinical trial History GI surgery ( except appendectomy occur 6 month prior screen History clinically significant recur active gastrointestinal symptom ( eg , nausea , diarrhea , dyspepsia , constipation ) within 3 month screen Chronic use ( 7 day ) medical therapy treat GI symptom within 1 month screening Has clinically significant medical condition observe abnormality screen History myocardial infarction , include silent myocardial infarction unstable angina History clinically significant drug alcohol abuse within past year prior screen Clinically significant history suicidal ideation suicidal behavior last 12 month Subject pregnant breastfeeding plan become pregnant begin breastfeed point study 30 day study drug administration Prior use Dimethyl Fumarate ( DMF ) Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>RRMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Alkermes</keyword>
	<keyword>ALKS 8700</keyword>
	<keyword>Dimethyl Fumarate</keyword>
	<keyword>DMF</keyword>
	<keyword>Tecfidera</keyword>
</DOC>